Centre for International Health, Education, and Biosecurity (Ciheb), University of Maryland School of Medicine, Baltimore, USA.
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
AIDS Behav. 2024 Feb;28(2):583-590. doi: 10.1007/s10461-023-04247-1. Epub 2023 Dec 21.
Multi-month dispensing (MMD) has been widely adopted by national HIV programs as a key strategy for improving the quality of HIV care and treatment services while meeting the unique needs of diverse client populations. We assessed the clinical outcomes of clients receiving MMD in Kenya by conducting a retrospective cohort study using routine programmatic data in 32 government health facilities in Kenya. We included clients who were eligible for multi-month antiretroviral therapy (ART) dispensing for ≥ 3 months (≥ 3MMD) according to national guidelines. The primary exposure was enrollment into ≥ 3MMD. The outcomes were lost to follow-up (LTFU) and viral rebound. Multilevel modified-Poisson regression models with robust standard errors were used to compare clinical outcomes between clients enrolled in ≥ 3MMD and those receiving ART dispensing for less than 3 months (< 3MMD). A total of 3,501 clients eligible for ≥ 3MMD were included in the analysis, of whom 65% were enrolled in ≥ 3MMD at entry into the cohort. There was no difference in LTFU of ≥ 180 days between the two types of care (aRR 1.1, 95% CI 0.7-1.6), while ≥ 3MMD was protective for viral rebound (aRR 0.1 95% CI 0.0-0.2). As more diverse client-focused service delivery models are being implemented, robust evaluations are essential to guide the implementation, monitor progress, and assess acceptability and effectiveness to deliver optimal people-centered care.
多月末(MMD)配药已被各国艾滋病毒规划广泛采用,是改善艾滋病毒护理和治疗服务质量,同时满足不同人群独特需求的关键策略。我们使用肯尼亚 32 家政府卫生机构的常规规划数据,通过回顾性队列研究,评估了接受 MMD 的肯尼亚患者的临床结局。我们纳入了符合国家指南多月末抗逆转录病毒治疗(ART)配药条件(≥3 个月,即≥3MMD)的患者。主要暴露因素是≥3MMD 配药。结局是失访(LTFU)和病毒反弹。使用具有稳健标准差的多级修正泊松回归模型,比较了接受≥3MMD 配药和接受<3 个月(<3MMD)ART 配药的患者的临床结局。共纳入 3501 名符合≥3MMD 条件的患者,其中 65%在进入队列时就开始接受≥3MMD 配药。两种治疗方案的 180 天以上 LTFU 无差异(调整比值比[aRR]1.1,95%置信区间[CI]0.7-1.6),而≥3MMD 对病毒反弹有保护作用(aRR 0.1,95%CI 0.0-0.2)。随着更多以患者为中心的服务提供模式的实施,进行强有力的评估至关重要,以便指导实施、监测进展,并评估接受度和有效性,从而提供最佳的以患者为中心的护理。